United States securities and exchange commission logo

                          September 7, 2022

       Barbara Weber
       President and Chief Executive Officer
       Tango Therapeutics, Inc.
       201 Brookline Avenue, Suite 901
       Boston, MA 02215

                                                        Re: Tango Therapeutics,
Statement on Form S-3
                                                            Filed September 1,
                                                            File No. 333-267224

       Dear Dr. Weber:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jordan
Nimitz at 202-551-5831 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences